WRBY
Warby Parker Inc. Health Care Ophthalmic Goods Russell 3000
$24.61Close
$16.49 – $30.3452-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 43 · weaker than 57% of stocks over 12 months
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
down 5.0%
price change
1mo
down 11.4%
price change
12-month return
up 28%
market up 11% ·
its own up 12%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 13%
year on year
EPS growth
—
latest quarter
Sales growth
up 10%
latest quarter · +1 pts
ROE
0%
return on equity
Free cash margin
up 5%
$43.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-6.4×
net cash
Interest cover
—EBIT / interest
Trade setup
ATR%
5.5%
$1.35 a day · 2×ATR $21.91
RS
43 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.88
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 55.3% to 54.0%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-10% vs market2 sessions after results
Financials
- Gross 54%
- Net 0%
- Free cash 5%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $393.7M | $540.8M | $598.1M | $669.8M | $771.3M | $871.9M |
| Gross margin | 59% | 59% | 57% | 55% | 55% | 54% |
| Operating income | -$55.6M | -$143.7M | -$111.2M | -$72.0M | -$30.1M | -$5.3M |
| Net income | -$55.9M | -$144.3M | -$110.4M | -$63.2M | -$20.4M | $1.6M |
| Net margin | -14% | -27% | -18% | -9% | -3% | 0% |
| Earnings per share | -$1.05 | -$2.02 | -$0.96 | -$0.54 | -$0.17 | $0.01 |
| Free cash flow | $12.7M | -$80.5M | -$49.8M | $7.3M | $34.7M | $43.7M |
| Free cash margin | 3% | -15% | -8% | 1% | 5% | 5% |
| Cash | $314.1M | $256.4M | $208.6M | $216.9M | $254.2M | $286.4M |
| Shareholders' equity | -$198.1M | $286.0M | $286.6M | $301.8M | $340.1M | $367.7M |
| Shares outstanding | 53.94m | — | — | — | — | — |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 26, 2026 | Results · Other events ↗ |
| Feb 9, 2026 | Director or officer change · Regulation FD ↗ |
| Dec 8, 2025 | Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results · Director or officer change ↗ |
| Jun 16, 2025 | Shareholder vote ↗ |
| May 20, 2025 | Unregistered share sale · Other events ↗ |
| May 8, 2025 | Results ↗ |
| Feb 27, 2025 | Results ↗ |